Subscribe to RSS - neb-meds

neb-meds

ASP: Winners, losers, audits

 - 
10/25/2013

BALTIMORE – With few exceptions, the average sales price (ASP) figures for nebulizer medications don’t change much from quarter to quarter. That doesn’t mean the market is stagnant, says Wayne Vega, senior vice president of the Inhalation Drug Group.

ASP: Budesonide gets big boost

 - 
09/10/2013

BALTIMORE – Things are looking up for several respiratory medications in the latest average sales price (ASP) figures. For the fourth quarter 2013, budesonide (J7626) took the biggest leap, up 85 cents to $5.95 per dose.

IDG offers Ritedose of help

 - 
05/07/2013

SOMERVILLE, N.J. – It’s not easy being a smaller provider of nebulizer medications in the world of “Big Pharma.”

Prices, audits stay the course

 - 
04/23/2012

BALTIMORE – Brand-name Brovana took a hit in the latest average sales price (ASP) figures for nebulizer medications, but otherwise there were few major changes.